Basiliximab
An anti-IL-2R alpha chimeric antibody.
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection
Protein factor Small molecule Antibody In silico |
in silico (machine learning) | 13.49 | Considered by the authors to be among the most relevant drugs identified in a machine-learning algorithm-based screening of compounds which considers causal protein-protein interactions, known drug targets, and specific signalling circuits in <a href= |
Dec/11/2020 |
AI-suggested references
| Link | Publication date |
|---|---|
|
Safety of Antithymocyte Globulin Use in Kidney Graft Recipients During the COVID-19 Pandemic
|
Jun/30/2020 |
Clinical trials
| ID | Title | Status | Phase | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05013034 | Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients | Not yet recruiting | Phase 2 | Oct/15/2021 | Dec/01/2022 |
|
|||||
